Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1 – 4 September 2025

Review will assess risk of leukoencephalopathy, a condition affecting the brainEMA’s safety committee (PRAC) has started a review of medicines containing levamisole, authorised in…, Agenda Agenda of the PRAC meeting 1-4 September 2025DraftReference Number: EMA/PRAC/234907/2025 English (EN…, PRAC statistics: September 2025 , PRAC statistics: September 2025 English (EN) (33.17 MB – PDF)First published: 05/09/2025View, Glossary Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association…